Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
Conference Coverage
ASCO: New hope for immunotherapy in advanced ovarian cancer
Publish date:
June 9, 2015
AT 2015 ASCO ANNUAL MEETING
References
pwendling@frontlinemedcom.com
On Twitter
@pwendl
Pages
« first
1
2
Recommended Reading
ACOG: Practice and referral patterns may affect occult uterine sarcoma risk post hysterectomy
MDedge Hematology and Oncology
AACR: HPV vaccine may protect some women with prior exposure
MDedge Hematology and Oncology
Managing open wounds in ob.gyn.
MDedge Hematology and Oncology
ACOG spells out risk assessment for hereditary cancer syndromes
MDedge Hematology and Oncology
ASCO 2015: Dr. Maurie Markman gives his top picks in gynecologic research
MDedge Hematology and Oncology
ACOG: Long-term low-dose vaginal estrogen poses no apparent cancer risk
MDedge Hematology and Oncology
VIDEO: Genomic biomarker predicts pembrolizumab response
MDedge Hematology and Oncology
ASCO: Precision medicine initiatives take wing
MDedge Hematology and Oncology
ASCO: MITO END-2 – Is endometrial cancer starting to catch up?
MDedge Hematology and Oncology
ASCO: Ascites may salvage trebananib in recurrent ovarian cancer
MDedge Hematology and Oncology
Gynecologic Cancer
All Specialties
